Abstract
Glial cell line‐derived neurotrophic factor (GDNF) affords neuroprotection in Parkinson’s disease in accordance with its ability to bolster nigrostriatal innervation. We previously found that GDNF facilitates dopamine release in a manner dependent on adenosine A2Areceptor activation. As motor dysfunction also involves modifications of striatal glutamatergic innervation, we now tested if GDNF and its receptor system, Ret (rearranged during transfection) and GDNF family receptor α1 controlled the cortico‐striatal glutamatergic pathway in an A2Areceptor‐dependent manner. GDNF (10 ng/mL) enhanced (by ≈13%) glutamate release from rat striatal nerve endings, an effect potentiated (up to ≈30%) by the A2Areceptor agonist CGS 21680 (10 nM) and prevented by the A2Areceptor antagonist, SCH 58261 (50 nM). Triple immunocytochemical studies revealed that Ret and GDNF family receptor α1 were located in 50% of rat striatal glutamatergic terminals (immunopositive for vesicular glutamate transporters‐1/2), where they were found to be co‐located with A2Areceptors. Activation of the glutamatergic system uponin vivoelectrical stimulation of the rat cortico‐striatal input induced striatal Ret phosphorylation that was prevented by pre‐treatment with the A2Areceptor antagonist, MSX‐3 (3 mg/kg). The results provide the first functional and morphological evidence that GDNF controls cortico‐striatal glutamatergic pathways in a manner largely dependent on the co‐activation of adenosine A2Areceptors.

This publication has 42 references indexed in Scilit: